The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis

Journal of Translational Medicine

Melchor Alvarez-Mon³  David Diaz⁴  Ignacio Sanz²  Antonio de la Hera⁴  Alfredo Prieto⁴  Jorge Monserrat⁴  Miguel A Sánchez⁴  Angel Asunsolo del Barco¹  Julio Chevarria³  Ana Turrión³  Fernando Albarrán³  Eduardo Cuende³  Ana Pérez³  Ana Sánchez-Atrio³  Luis Chara⁴ 

[1] Department of Health and Medical Social Sciences, University of Alcalá, Madrid, Spain;Division of Allergy, Immunology and Rheumatology, Department of Medicine, Emory University, Atlanta, GA, USA;Immune System Diseases-Rheumatology and Oncology Service, University Hospital “Príncipe de Asturias”, Alcalá de Henares, Madrid, Spain;Department of Medicine, University of Alcalá, Carretera Madrid-Barcelona km 33.600, Alcalá de Henares, 28871, Madrid, Spain

关键词: Biomarker;    Clinical response;    Methotrexate;    Monocyte;    Rheumatoid arthritis;   

Others  :  1146396
DOI  :  10.1186/s12967-014-0375-y

 received in 2014-10-15, accepted in 2014-12-26,  发布年份 2015

【 摘 要 】

Background

The aim of this work was to analyze the number and distribution of circulating monocytes, and of their CD14^+highCD16⁻, CD14^+highCD16⁺ and CD14^+lowCD16⁺ subset cells, in treatment-naive patients with rheumatoid arthritis (RA), and to determine their value in predicting the clinical response to methotrexate (MTX) treatment.

Methods

This prospective work investigated the number of circulating monocytes, and the numbers of CD14^+highCD16⁻, CD14^+highCD16⁺ and CD14^+lowCD16⁺ subset cells, in 52 untreated patients with RA before MTX treatment, and at 3 and 6 months into treatment, using flow cytometry.

Results

The absolute number of circulating monocytes, and the numbers of CD14^+highCD16⁻, CD14^+highCD16⁺ and CD14^+lowCD16⁺ subset cells, were significantly higher in MTX non-responders than in responders and healthy controls before starting and throughout treatment. Responders showed normal numbers of monocytes, and of their subset cells, over the study period. The pre-treatment absolute number of circulating monocytes, and the numbers of CD14^+highCD16⁻ and CD14^+highCD16⁺ subset cells, were found to be predictive of the clinical response to MTX, with a sensitivity and specificity of >70% and >88%, respectively.

Conclusions

Treatment-naive patients with RA showed an anomalous distribution of circulating monocyte subsets, and an anomalous number of cells in each subset. A higher pre-treatment number of circulating monocytes, and higher numbers of CD14^+highCD16⁻ and CD14^+highCD16⁺ subset cells, predict a reduced clinical response to MTX in untreated patients with RA.

【 授权许可】

   
2015 Chara et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet 2010, 376:1094-108.
• [2]Gibbons LJ, Hyrich KL: Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 2009, 23:111-24.
• [3]Bergman MJ: Assessing adequate treatment response in patients with rheumatoid arthritis. Clin Ther 2009, 31:1219-31.
• [4]Auffray C, Sieweke MH, Geissmann F: Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-92.
• [5]Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N: Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 2006, 8:R152. BioMed Central Full Text
• [6]Grage-Griebenow E, Flad HD, Ernst M: Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001, 69:11-20.
• [7]Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-64.
• [8]Geissmann F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
• [9]Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB: Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116(16):e74-80.
• [10]Szekanecz Z, Koch AE: Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007, 19:289-95.
• [11]Robbins CS, Swirski FK: The multiple roles of monocyte subsets in steady state and inflammation. Cell Mol Life Sci 2010, 67:2685-93.
• [12]Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verheijden GF, Berheijden G, Miltenburg AM, Rijnders AW, Veys EM, De Keyser F: Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000, 43:1233-43.
• [13]Rau R: Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol 2010, 28:S58-64.
• [14]Bansard C, Lequerré T, Daveau M, Boyer O, Tron F, Salier JP, Vittecoq O, Le-Loët X: Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford) 2009, 48:1021-8.
• [15]Chara L, Sánchez-Atrio A, Pérez A, Cuende E, Albarrán F, Turrión A, Chevarria J, Sánchez MA, Monserrat J, de la Hera A, Prieto A, Sanz I, Diaz D, Alvarez-Mon M: Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Res Ther 2012, 14(4):R175. BioMed Central Full Text
• [16]van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39(1):34-40.
• [17]González VM, Stewart A, Ritter PL, Lorig K: Translation and validation of arthritis outcome measures into Spanish. Arthritis Rheum 1995, 38:1429-46.
• [18]Böyum AJ: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968, 21:77-89.
• [19]Swierkot J, Szechiński J: Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006, 58(4):473-92.
• [20]Feely MG, Erickson A, O'Dell JR: Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother 2009, 10(13):2095-106.
• [21]Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C: Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res 2010, 62(8):1128-43.
• [22]Ponchel F, Goëb V, Parmar R, El-Sherbiny Y, Boissinot M, El Jawhari J, Burska A, Vital EM, Harrison S, Conaghan PG, Hensor E, Emery P: An immunological biomarker to predict MTX response in early RA. Ann Rheum Dis 2013, 73(11):2047-53.
• [23]van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, Jackman AL, Kraan MC, Tak PP, Ratnam M, Jansen G: Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009, 60:12-21.
• [24]Phillips DC, Woollard KJ, Griffiths HR: The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003, 138:501-11.
• [25]Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C: Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008, 153:188-95.
• [26]Fabre S, Guisset C, Tatem L, Dossat N, Dupuy AM, Cohen JD, Cristol JP, Daures JP, Jorgensen C: Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009, 155:395-402.
• [27]Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M, Ueno A, Ohmoto Y, Makino H: CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002, 46:2578-86.
• [28]Cairns AP, Crockard AD, Bell AL: The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 2002, 21:189-92.
• [29]Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U: The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012, 64(3):671-7.
• [30]Fingerle-Rowson G, Angstwurm M, Andreesen R, Ziegler-Heitbrock HW: Selective depletion of CD14+CD16+ monocytes by glucocorticoid therapy. Clin Exp Immunol 1998, 112:501-6.
• [31]Dayyani F, Belge KU, Frankenberger M, Mack M, Berki T, Ziegler-Heitbrock L: Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J Leukoc Biol 2003, 74:33-9.
• [32]Krasselt M, Baerwald C, Wagner U, Rossol M: CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther 2013, 15(5):R139. BioMed Central Full Text
• [33]Wessels JA, Huizinga TW, Guchelaar HJ: Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:249-55.
• [34]Möller B, Kukoc-Zivojnov N, Okamgba S, Kessler U, Puccetti E, Ottmann OG, Kaltwasser JP, Hoelzer D, Ruthardt M: Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors. Rheumatol Int 2002, 22:60-7.
• [35]Strauss G, Osen W, Debatin KM: Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002, 128:255-66.
• [36]Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA: Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:1189-96.